Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 2:21 PM ET


Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studi...

175 Portland Street

4th Floor

Boston, MA 02114

United States

Founded in 2005

38 Employees



Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $425.0K
Age: 52
Total Annual Compensation: $195.4K
Chief Financial Officer
Age: 53
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 45
Total Annual Compensation: $407.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

Zafgen, Inc. Key Developments

European Commission Grants Orphan Drug Designation for Beloranib of Zafgen, Inc. for the Treatment of Craniopharyngiom

Zafgen, Inc. announced that the European Commission (EC) has granted orphan drug designation for beloranib for the treatment of craniopharyngioma, a rare form of benign brain tumor. Severe and intractable weight gain is a frequent manifestation of craniopharyngioma, which is the most common cause of hypothalamic injury-associated obesity, or HIAO. Orphan Drug Designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, Orphan Drug Designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to centralized marketing authorization. Beloranib is a novel, first-in-class injectable small molecule therapy with a unique mechanism of action that reduces hunger while stimulating the use of stored fat as an energy source. Beloranib is a potent inhibitor of methionine aminopeptidase 2, or MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism. MetAP2 inhibitors work, at least in part, by directing MetAP2 binding to cellular stress mediators, and, thus, reducing the tone of signals that drive lipid synthesis by the liver and fat storage throughout the body. In this manner, MetAP2 inhibition increases metabolism of fat as an energy source. Zafgen holds exclusive worldwide rights (exclusive of South Korea) for the development and commercialization of beloranib. Zafgen exclusively licensed beloranib from Chong Kun Dang (CKD) Pharmaceutical Corp. of South Korea.

Zafgen, Inc. Announces Management Changes

Zafgen, Inc. announced the appointment of Robert Perez and Geoffrey McDonough, M.D., to its board of directors. Mr. Perez is the former Chief Executive Officer of Cubist Pharmaceuticals, and brings over 28 years of experience from various leadership and senior management positions in the life sciences industry. Mr. Perez has a wealth of experience in guiding corporate strategy in the biotechnology industry, with a focus on drug development and commercialization. In addition, Kevin Starr and Avi Goldberg will be resigning from Zafgen's Board of Directors effective as of December 8, 2015 as transition the board with the appointment of Robert Perez and Geoffrey McDonough, M.D.

Zafgen, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 12:55 PM

Zafgen, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 12:55 PM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Auspex Pharmaceuticals, Inc. United States
CoTherix, Inc. United States
EQALIX Inc United States
EnviroGro Solutions, Inc. United States
A-CUBE, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zafgen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at